Thank you, Lisa, and thanks for joining us. The biopharmaceutical and Diagnostic Solutions segment delivered another solid ...

Argenx delivered Q4 2025 product net sales of $1.3B and $4.2B for the full year, up 90% year over year as VYVGART demand accelerated globally. The company reported Q4 operating profit of $367M and ...

Xeris Biopharma benefits from the FDA's CRL to Corcept's relacorilant, removing a major competitive threat to Recorlev sales ...

Stevanato Group (NYSE:STVN) executives said the company closed fiscal 2025 with “solid” results and entered 2026 with positive momentum, driven by continued strength in its Biopharmaceutical and Diagn ...

New South Carolina long snapper Emmet Rhoades plays football despite being a Type 1 diabetic. He talked about his diagnosis ...

Tyler Van Buren here, senior biotech analyst at TD Cowen. Thank you very much for joining TD Cowen's 46th Annual Healthcare Conference. For next session or first session of the day, actually, very ...